Cardiovascular (CV)
American Heart Association (AHA) 2024
Congress Details
November 16-18, 2024
Chicago, IL, USA
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Congress Materials
Presentation Type
Location
Presenter
Related Materials
Cardiovascular (CV)
Add-on Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial
Journal of the American Medical Association
Cardiovascular (CV)
European Society of Cardiology (ESC) 2024
Cardiovascular (CV)
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial
The Journal of the American Medical Association
Cardiovascular (CV)
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
New England Journal of Medicine
Cardiovascular (CV)
Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease
Hypertension
Cardiovascular (CV)
No evidence for brain renin-angiotensin system activation during DOCA-salt hypertension
Clinical Science
